EGFR and neoplasm: First- and second-generation TKIs, such as gefitinib, erlotinib, afatinib, and dacomitinib, are used continuously until evidence of tumor resistance, which happen frequently by the selection of a secondary mutation in the kinase domain of the EGFR, particularly T790M (52).